Tasly ：rhPro-UK Phase II Data for Pulmonary Embolism Released
Recently, the results of the pivotal ERUPTE Phase II clinical trial, led by Professor Jing Zhicheng from Guangdong Provincial People’s Hospital, were officially published in Med, a Cell Press journal. This study represents a breakthrough in the global development of novel thrombolytic drugs for pulmonary embolism (PE), an area that has seen little progress for nearly 35 years.
The rigorous randomized controlled trial demonstrated that recombinant human prourokinase (rhPro-UK), a Category 1 domestic innovative biologic drug, is comparable to the imported classic thrombolytic agent alteplase (rt-PA) in improving pulmonary hemodynamics for the treatment of high-risk and intermediate-high-risk acute PE. Moreover, rhPro-UK significantly reduced the incidence of non-major bleeding events, offering a potentially safer option for thrombolytic therapy in acute PE.
Buy rhPro-UK online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
